Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Crizotinib neuroblastoma study 'very promising'

  • Comment

A new way of using a drug called crizotinib in combination with a second class of drugs to treat neuroblastoma has shown “very promising” results, scientists said.

Researchers at The Institute of Cancer Research in London used crizotinib with mTOR inhibitors to overcome the resistance of cancer cells, the paper published in the journal Cancer Cell revealed.

Early experience of crizotinib in the US, where it has already been licensed for use in adult cancers, indicates that tumours develop additional mutations in the ALK gene targeted by the drug and, ultimately, stop responding to the treatment.

Senior author Dr Louis Chesler, leader of the neuroblastoma drug development team at The Institute of Cancer Research and honorary consultant at The Royal Marsden NHS Foundation Trust, described the results when using crizotinib with an mTOR inhibitor as “very promising”.

“Many mTOR inhibitors are already in adult clinical trials,” he added.

The research was led by The Institute of Cancer Research in collaboration with the Dana-Farber Cancer Institute and Children’s Hospital in Boston.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.